These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8777981)

  • 41. Drug choice in preventing postoperative Crohn's disease.
    Korelitz BI
    Gastroenterology; 1996 Feb; 110(2):652-3. PubMed ID: 8566620
    [No Abstract]   [Full Text] [Related]  

  • 42. Interstitial pneumonitis due to mesalamine.
    Pascual-Lledó JF; Calvo-Bonachera J; Carrasco-Miras F; Sanchez-Martínez H
    Ann Pharmacother; 1997 Apr; 31(4):499. PubMed ID: 9101017
    [No Abstract]   [Full Text] [Related]  

  • 43. Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? A case with mesalamine.
    Sossai P; Cappellato MG; Stefani S
    Mt Sinai J Med; 2001 Nov; 68(6):389-95. PubMed ID: 11687867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute renal failure in a 53-year-old woman with Crohn's disease treated with 5-aminosalicylic acid.
    Haas M; Shetye KR
    Am J Kidney Dis; 2001 Jul; 38(1):205-9. PubMed ID: 11431204
    [No Abstract]   [Full Text] [Related]  

  • 45. [Drug therapy of chronic inflammatory intestinal diseases].
    Raedler A; Reinecker C
    Immun Infekt; 1990 Aug; 18(4):121-6. PubMed ID: 2210794
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ro-positive interstitial lung disease treated with cyclophosphamide.
    Habib Bedwani N; Jefferson N; Marguerie C; Mukherjee J
    BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29789305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case of cryptogenic organizing pneumonia occurring in Crohn's disease.
    Carratú P; Dragonieri S; Nocerino MC; Trabucco SM; Lacedonia D; Parisi G; Resta O
    Can Respir J; 2005; 12(8):437-9. PubMed ID: 16331316
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Severe chronic interstitial nephritis associated with Crohn's disease, but not with mesalazine?].
    Baumer P; Brocard JF; Kohn W; Bedossa P; Charpentier B
    Gastroenterol Clin Biol; 1999 Dec; 23(12):1400-2. PubMed ID: 10642629
    [No Abstract]   [Full Text] [Related]  

  • 50. Multiple pulmonary nodules in a patient with Crohn's disease.
    Golpe R; Mateos A; Pérez-Valcárcel J; Lapeña JA; García-Figueiras R; Blanco J
    Respiration; 2003; 70(3):306-9. PubMed ID: 12915753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.
    Griffiths B; Miles S; Moss H; Robertson R; Veale D; Emery P
    J Rheumatol; 2002 Nov; 29(11):2371-8. PubMed ID: 12415594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methotrexate-induced pneumonitis in a patient with Crohn's disease.
    Margagnoni G; Papi V; Aratari A; Triolo L; Papi C
    J Crohns Colitis; 2010 Jun; 4(2):211-4. PubMed ID: 21122509
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.
    Tremaine WJ; Schroeder KW; Harrison JM; Zinsmeister AR
    J Clin Gastroenterol; 1994 Dec; 19(4):278-82. PubMed ID: 7876505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Herpes simplex-associated exacerbation of Crohn's disease. Successful treatment with acyclovir].
    Rüther U; Nunnensiek C; Müller HA; Rupp W; Gförer S; Bader H; Stilz S; Jipp P
    Dtsch Med Wochenschr; 1992 Jan; 117(2):46-50. PubMed ID: 1309692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mesalazine as maintenance treatment in Crohn's disease.
    Vos J; Lesterhuis W
    Gastroenterology; 1994 Feb; 106(2):553-4. PubMed ID: 8299923
    [No Abstract]   [Full Text] [Related]  

  • 58. [Pulmonary manifestations of crohn's disease or chronic pharmacotherapy complications? - case report].
    Rakoczy I; Liczek M; Panek I; Panek M; Małecka-Panas E; Talar-Wojnarowska R
    Wiad Lek; 2020; 73(1):196-200. PubMed ID: 32124834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
    Singleton JW; Hanauer S; Robinson M
    Dig Dis Sci; 1995 May; 40(5):931-5. PubMed ID: 7729281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations.
    Foster RA; Zander DS; Mergo PJ; Valentine JF
    Inflamm Bowel Dis; 2003 Sep; 9(5):308-15. PubMed ID: 14555914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.